Sebastien Lacroix-Desmazes

List of Publications by Year
in descending order

72 papers	3,065 citations	201674 27 h-index	161849 54 g-index
74 all docs	74 docs citations	74 times ranked	3009 citing authors

#	Article	IF	Citations
1	Cutting Edge: Human CD4+CD25+ T Cells Restrain the Maturation and Antigen-Presenting Function of Dendritic Cells. Journal of Immunology, 2004, 172, 4676-4680.	0.8	415
2	Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 2008, 111, 715-722.	1.4	252
3	IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nature Medicine, 2020, 26, 1096-1101.	30.7	193
4	Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nature Medicine, 1999, 5, 1044-1047.	30.7	186
5	VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood, 2007, 109, 610-612.	1.4	179
6	High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4109-4113.	7.1	110
7	A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8965-8970.	7.1	110
8	The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A. New England Journal of Medicine, 2002, 346, 662-667.	27.0	107
9	Antibody Polyreactivity in Health and Disease: Statu Variabilis. Journal of Immunology, 2013, 191, 993-999.	0.8	100
10	Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nature Clinical Practice Rheumatology, 2007, 3, 262-272.	3.2	94
11	Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood, 2008, 112, 240-249.	1.4	80
12	Inhibitors in hemophilia A. Blood Coagulation and Fibrinolysis, 2004, 15, 109-124.	1.0	75
13	Ferrous Ions and Reactive Oxygen Species Increase Antigen-binding and Anti-inflammatory Activities of Immunoglobulin G. Journal of Biological Chemistry, 2006, 281, 439-446.	3.4	72
14	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125.	1.4	63
15	Tolerating Factor VIII: Recent Progress. Frontiers in Immunology, 2019, 10, 2991.	4.8	52
16	Catalytic IgG from Patients with Hemophilia A Inactivate Therapeutic Factor VIII. Journal of Immunology, 2006, 177, 1355-1363.	0.8	45
17	Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia. Journal of Immunology, 2008, 180, 7714-7720.	0.8	45
18	Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Science Translational Medicine, 2015, 7, 275ra21.	12.4	43

#	Article	IF	Citations
19	Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica, 2007, 92, 1423-1426.	3.5	40
20	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 2011, 117, 2257-2264.	1.4	38
21	Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica, 2015, 100, 149-156.	3.5	37
22	Immunogenicity of long-lasting recombinant factor VIII products. Cellular Immunology, 2016, 301, 40-48.	3.0	37
23	Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica, 2008, 93, 83-89.	3.5	34
24	Autoantibodies with enzymatic properties in human autoimmune diseases. Journal of Autoimmunity, 2011, 37, 144-150.	6.5	34
25	CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naÃ¯ve and memory cells. Blood Advances, 2017, 1, 1842-1847.	5.2	32
26	The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica, 2017, 102, 271-281.	3.5	29
27	Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica, 2013, 98, 1650-1655.	3.5	29
28	Induction of heme oxygenase-1 in factor VIIIâ€“deficient mice reduces the immune response to therapeutic factor VIII. Blood, 2010, 115, 2682-2685.	1.4	28
29	Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochemical and Biophysical Research Communications, 2010, 398, 266-271.	2.1	27
30	A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. Clinical Reviews in Allergy and Immunology, 2009, 37, 105-113.	6.5	24
31	Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmunity Reviews, 2013, 12, 648-652.	5.8	24
32	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. Diabetes, 2015, 64, 3532-3542.	0.6	24
33	Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?. Haematologica, 2019, 104, 236-244.	3.5	23
34	Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients. Journal of Immunology, 2008, 180, 8455-8460.	0.8	22
35	A Cryptic Polyreactive Antibody Recognizes Distinct Clades of HIV-1 Glycoprotein 120 by an Identical Binding Mechanism. Journal of Biological Chemistry, 2014, 289, 17767-17779.	3.4	19
36	Functional variability of antibodies upon oxidative processes. Autoimmunity Reviews, 2008, 7, 574-578.	5.8	18

#	Article	IF	Citations
37	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. Journal of Immunology, 2008, 181, 1609-1615.	0.8	18
38	Factor VIIIâ€hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters, 2009, 583, 2565-2572.	2.8	18
39	Thermodynamic Analysis of the Interaction of Factor VIII with von Willebrand Factor. Biochemistry, 2012, 51, 4108-4116.	2.5	17
40	Complement C3 is a novel modulator of the anti-factor VIII immune response. Haematologica, 2018, 103, 351-360.	3.5	17
41	Noncanonical Functions of Antibodies. Trends in Immunology, 2020, 41, 379-393.	6.8	17
42	Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. Journal of Allergy and Clinical Immunology, 2012, 129, 1172-1173.	2.9	16
43	Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. Journal of Immunological Methods, 2014, 407, 26-34.	1.4	16
44	Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A. Thrombosis and Haemostasis, 2003, 90, 813-822.	3.4	15
45	The role of VWF in the immunogenicity of FVIII. Thrombosis Research, 2008, 122, S3-S6.	1.7	15
46	Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. Haematologica, 2020, 105, 1129-1137.	3.5	15
47	A novel molecular analysis of genes encoding catalytic antibodies. Molecular Immunology, 2012, 50, 160-168.	2.2	13
48	â€œRational Vaccine Designâ€•for HIV Should Take into Account the Adaptive Potential of Polyreactive Antibodies. PLoS Pathogens, 2011, 7, e1002095.	4.7	12
49	Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A. PLoS ONE, 2019, 14, e0218258.	2.5	12
50	Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy. Haemophilia, 2020, 26, 958-965.	2.1	11
51	Key insights to understand the immunogenicity of FVIII products. Thrombosis and Haemostasis, 2016, 116, S2-S9.	3.4	10
52	Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective. Seminars in Thrombosis and Hemostasis, 2018, 44, 517-530.	2.7	10
53	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Frontiers in Immunology, 2020, 11, 810.	4.8	10
54	Absence of a neutralizing antibody response to humanized cobra venom factor in mice. Molecular Immunology, 2018, 97, 1-7.	2.2	9

#	Article	IF	Citations
55	Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation. Thrombosis and Haemostasis, 2010, 104, 1093-1098.	3.4	8
56	Emergence of antibodies endowed with proteolytic activity against High-mobility group box 1 protein (HMGB1) in patients surviving septic shock. Cellular Immunology, 2020, 347, 104020.	3.0	7
57	Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. Expert Review of Clinical Immunology, 2007, 3, 677-681.	3.0	6
58	Inhibitorsâ€"Recent insights. Haemophilia, 2021, 27, 28-36.	2.1	6
59	Catalytic antibodies in patients with systemic lupus erythematosus. European Journal of Rheumatology, 2018, 5, 173-178.	0.6	6
60	Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. Blood Coagulation and Fibrinolysis, 2006, 17, 229-234.	1.0	4
61	Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Cellular Immunology, 2018, 325, 64-68.	3.0	4
62	Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors. Cellular Immunology, 2018, 331, 22-29.	3.0	4
63	Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A. Haematologica, 2019, 104, 1046-1054.	3.5	4
64	Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica, 2019, 104, e369-e372.	3.5	4
65	Inhibitors of Factor VIII in Hemophilia. New England Journal of Medicine, 2009, 361, 308-310.	27.0	3
66	Varied Immune Response to FVIII: Presence of Proteolytic Antibodies Directed to Factor VIII in Different Human Pathologies. Clinical Reviews in Allergy and Immunology, 2009, 37, 97-104.	6.5	3
67	Maternally transferred antiâ€factor VIII IgG reduce the antiâ€factor VIII humoral immune response in factor VIIIâ€deficient mice. Immunology, 2010, 131, 549-555.	4.4	3
68	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individualâ€™s Immune System: A Study on a Large Cohort of Renal Transplant Patients. Journal of Immunology, 2016, 196, 4075-4081.	0.8	3
69	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. Frontiers in Immunology, 2020, 11, 393.	4.8	3
70	IVIg Treatment Reduces Catalytic Antibody Titers of Renal Transplanted Patients. PLoS ONE, 2013, 8, e70731.	2.5	3
71	A molecular jewel for hemophilia A treatment. Blood, 2020, 135, 1417-1419.	1.4	2
72	Monoepitopic anti-FVIII T-cell response. Blood, 2016, 128, 1999-2001.	1.4	1